2024
Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Yurtsever N, Binns T, Hendrickson J, Tormey C, Lee E. Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma. Lab Medicine 2024, lmae054. PMID: 39038224, DOI: 10.1093/labmed/lmae054.Peer-Reviewed Original Research
2021
Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraQuality-adjusted life yearsIntensive care unitTherapeutic plasma exchangeHERCULES trialCost-effectiveness analysisCaplacizumab treatmentRituximab useTITAN trialHospital lengthTPE sessionsThrombocytopenic purpuraTreatment armsAcquired Thrombotic Thrombocytopenic PurpuraLong-term disease courseThrombotic microangiopathy leadingEnd-organ damagePlatelet count recoveryLong-term followHealth system perspectiveOne-way sensitivity analysesPotential confounding factorsCost-effectiveness ratioLife-threatening disease